Climb Bio
MA - Wellesley HillsBiotechnology
Focus: Climb Bio is a biotech company focused on treatments for neuronal excitability disorders and immune-mediated diseases, currently in early-stage clinical development with a lead program in kidney disease.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
Open Jobs
2+1 this month
Stable — net +1 jobs in 30d
2 added, 1 removed. Backfill posture.
Should You Work at Climb Bio?
AI assessmentClimb Bio is an early-stage clinical biotech with promising regulatory signals but severely limited hiring, making it suitable only for specialized finance roles or those accepting early-stage risk for equity upside.
Why Work Here
- FDA fast track designation on lead kidney disease program (Budoprutug) signals regulatory confidence and potential accelerated pathway
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
5 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Budoprutug
Healthy VolunteersClinical Trials (1)
NCT07090655A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteers
Phase 1Help build intelligence for Climb Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.